Development of combination adjuvant for efficient T cell and antibody response induction against protein antigen

Most current clinical vaccines work primarily by inducing the production of neutralizing antibodies against pathogens. Vaccine adjuvants that efficiently induce T cell responses to protein antigens need to be developed. In this study, we developed a new combination adjuvant consisting of 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), D35, and an aluminum salt. Among the various combinations tested, the DOTAP/D35/aluminum salt adjuvant induced strong T cell and antibody responses against the model protein antigen with a single immunization. Adjuvant component and model antigen interaction studies in vitro also revealed that the strong mutual interactions among protein antigens and other components were one of the important factors for this efficient immune induction by the novel combination adjuvant. In addition, in vivo imaging of the antigen distribution suggested that the DOTAP component in the combination adjuvant formulation elicited transient antigen accumulation at the draining lymph nodes, possibly by antigen uptake DC migration. These results indicate the potential of the new combination adjuvant as a promising vaccine adjuvant candidate to treat infectious diseases and cancers.

Automated summary

The DOTAP/D35/aluminum salt adjuvant developed in this study induced strong T cell and antibody responses against a model protein antigen with a single immunization. In vitro studies showed that strong mutual interactions among the adjuvant component and the model antigen were important factors for this efficient immune induction. In vivo imaging of the antigen distribution indicated that the DOTAP component in the adjuvant formulation elicited transient antigen accumulation at draining lymph nodes, possibly by antigen uptake DC migration.